Coming Up: Case on outlawed FDCs

| Updated on January 09, 2018


Patient advocacy groups and the pharmaceutical industry will be watching the fixed dose combination (FDC) medicine case, scheduled to come up in the Supreme Court this fortnight. An FDC combines two ormore medicines in one product and questions were raised on the rationale for such drugs: Whether companies were driven by scientific or commercial reasons to develop such medicines. Subsequently, the Centre banned 344 FDCs. And after many legal twists and turns, the final case comes up for hearing. The outcome will be important as the government increasingly exercises greater regulatory supervision on medicines in public interest.

Published on December 12, 2017

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

This article is closed for comments.
Please Email the Editor

You May Also Like